Lysoway Therapeutics raised $2.93 million to develop small-molecule modulators of lysosomal ion channels, including TRPML1 and TMEM175, to restore autophagic flux and enhance plasma membrane repair, enabling treatment of neurodegenerative and rare diseases caused by lysosomal dysfunction.
